i-SENS, Inc. (099190.KQ)
KRW 15170.0
(1.81%)
KRW 15170.0
(1.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 101.04 Billion KRW | -0.26% |
| 2022 | 101.3 Billion KRW | 2.24% |
| 2021 | 99.08 Billion KRW | 7.85% |
| 2020 | 91.87 Billion KRW | 11.21% |
| 2019 | 82.61 Billion KRW | 9.47% |
| 2018 | 75.47 Billion KRW | 13.44% |
| 2017 | 66.53 Billion KRW | 11.05% |
| 2016 | 59.91 Billion KRW | 36.77% |
| 2015 | 43.8 Billion KRW | 8.37% |
| 2014 | 40.41 Billion KRW | 14.72% |
| 2013 | 35.23 Billion KRW | 56.22% |
| 2012 | 22.55 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 70.34 Billion KRW | 5.63% |
| 2024 Q1 | 27.5 Billion KRW | -3.43% |
| 2024 Q2 | 27.14 Billion KRW | -1.3% |
| 2023 Q2 | 23.02 Billion KRW | -3.53% |
| 2023 FY | 101.04 Billion KRW | -0.26% |
| 2023 Q1 | 23.87 Billion KRW | 6.24% |
| 2023 Q3 | 25.65 Billion KRW | 11.42% |
| 2023 Q4 | 28.48 Billion KRW | 11.02% |
| 2022 Q2 | 25.31 Billion KRW | -10.97% |
| 2022 Q1 | 28.43 Billion KRW | 23.99% |
| 2022 FY | 101.3 Billion KRW | 2.24% |
| 2022 Q4 | 22.47 Billion KRW | -9.55% |
| 2022 Q3 | 24.84 Billion KRW | -1.85% |
| 2021 FY | 99.08 Billion KRW | 7.85% |
| 2021 Q2 | 26.78 Billion KRW | 17.77% |
| 2021 Q3 | 26.69 Billion KRW | -0.33% |
| 2021 Q1 | 22.74 Billion KRW | -4.31% |
| 2021 Q4 | 22.92 Billion KRW | -14.12% |
| 2020 Q3 | 24.58 Billion KRW | -1.24% |
| 2020 FY | 91.87 Billion KRW | 11.21% |
| 2020 Q4 | 23.77 Billion KRW | -3.3% |
| 2020 Q2 | 24.89 Billion KRW | 10.42% |
| 2020 Q1 | 22.54 Billion KRW | -2.4% |
| 2019 FY | 82.61 Billion KRW | 9.47% |
| 2019 Q4 | 23.09 Billion KRW | 4.7% |
| 2019 Q3 | 22.05 Billion KRW | -0.98% |
| 2019 Q2 | 22.27 Billion KRW | 15.12% |
| 2019 Q1 | 19.35 Billion KRW | -8.99% |
| 2018 Q3 | 21.37 Billion KRW | 20.28% |
| 2018 FY | 75.47 Billion KRW | 13.44% |
| 2018 Q2 | 17.77 Billion KRW | 2.62% |
| 2018 Q1 | 17.31 Billion KRW | -6.89% |
| 2018 Q4 | 21.26 Billion KRW | -0.52% |
| 2017 Q2 | 17.27 Billion KRW | 5.79% |
| 2017 FY | 66.53 Billion KRW | 11.05% |
| 2017 Q1 | 16.33 Billion KRW | -1.16% |
| 2017 Q3 | 16.99 Billion KRW | -1.67% |
| 2017 Q4 | 18.59 Billion KRW | 9.45% |
| 2016 FY | 59.91 Billion KRW | 36.77% |
| 2016 Q2 | 16.24 Billion KRW | 21.29% |
| 2016 Q1 | 13.39 Billion KRW | 15.39% |
| 2016 Q3 | 15.66 Billion KRW | -3.62% |
| 2016 Q4 | 16.52 Billion KRW | 5.53% |
| 2015 Q1 | 9.47 Billion KRW | -16.4% |
| 2015 Q4 | 11.6 Billion KRW | -5.63% |
| 2015 Q2 | 12.01 Billion KRW | 26.87% |
| 2015 Q3 | 12.3 Billion KRW | 2.38% |
| 2015 FY | 43.8 Billion KRW | 8.37% |
| 2014 Q3 | 10.06 Billion KRW | 0.18% |
| 2014 FY | 40.41 Billion KRW | 14.72% |
| 2014 Q1 | 8.98 Billion KRW | -6.28% |
| 2014 Q4 | 11.33 Billion KRW | 12.62% |
| 2014 Q2 | 10.04 Billion KRW | 11.76% |
| 2013 Q1 | 7.31 Billion KRW | 12.18% |
| 2013 Q2 | 9.09 Billion KRW | 24.34% |
| 2013 FY | 35.23 Billion KRW | 56.22% |
| 2013 Q3 | 9.23 Billion KRW | 1.47% |
| 2013 Q4 | 9.58 Billion KRW | 3.87% |
| 2012 Q3 | 5.25 Billion KRW | 0.0% |
| 2012 Q4 | 6.52 Billion KRW | 24.0% |
| 2012 FY | 22.55 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 219.75 Billion KRW | 54.022% |
| InBody Co.,Ltd | 128.11 Billion KRW | 21.132% |
| Curexo Inc. | 17.95 Billion KRW | -462.707% |
| Seegene, Inc. | 180.07 Billion KRW | 43.888% |
| Ray Co., Ltd. | 65.08 Billion KRW | -55.238% |
| Gencurix Inc. | 422.03 Million KRW | -23841.577% |
| Sugentech Inc. | -5.88 Billion KRW | 1818.138% |
| L&C Bio Co., Ltd | 32.52 Billion KRW | -210.635% |